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Background: Peripheral blood monocyte count is an easily assessable parameter of systemic inflammatory
response. The aim of this study was to determine whether monocyte count was prognostic in hepatocellular
carcinoma (HCC) following hepatic resection.
Methods: We retrospectively reviewed 351 patients with HCC treated with hepatic resection from 2006 to 2009.
Preoperative absolute peripheral monocyte count, demographics, and clinical and pathological data were analyzed.
Results: On univariate and multivariate analysis, elevated monocyte counts (≥545/mm3), tumor size ≥5 cm,
non-capsulation, and multiple tumors were associated with poor disease-free survival (DFS) and overall survival
(OS). The 1-, 3- and 5-year DFS rates were 58%, 41% and 35%, respectively, for patients with monocyte counts <545/mm3,
and 36%, 23% and 21% for patients with monocyte counts ≥545/mm3. Correspondingly, the 1-, 3- and 5-year OS rates
were 79%, 53% and 46% for monocyte counts <545/mm3, and 64%, 36% and 29% for monocyte counts ≥545/mm3.
Subgroup analysis indicated that DFS after hepatic resection in hepatitis B virus (HBV)-infected patients was significantly
better in those with a peripheral blood monocyte counts <545/mm3, but it did not differ between patients
without HBV infection. In addition, DFS was significantly better for patients with a peripheral blood monocyte
count <545/mm3, whether or not cirrhosis was present. Patients with elevated monocyte counts tended to have
larger tumors.
Conclusions: Elevated preoperative monocyte count is an independent predictor of worse prognosis for patients
with HCC after hepatic resection, especially for those with HBV infection. Postoperative adjuvant treatment might
be considered for patients with elevated preoperative monocyte counts.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most frequent cause of cancer-
related death [1]. Hepatic resection is one of the most
effective treatments for HCC. However, even after hepatic
resection, the long-term prognosis has remained far from
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unless otherwise stated.Therapies such as re-operation, percutaneous ablation,
and transcatheter arterial chemoembolization (TACE)
might be considered for recurrent HCC [2-4]. Unfortu-
nately, however, there are limited or no therapeutic op-
tions for a large number of patients when recurrence is
found. It is therefore critical to define reliable prognostic
factors that may help identify patients at high risk of recur-
rence. In addition, this group of patients might benefit from
postoperative adjuvant therapy against recurrence [3,4].
Prognostic factors identified in previous studies in-
clude tumor stage, serum α-fetoprotein (AFP), vascular
invasion, tumor size, and poor tumor differentiation [2].
Novel immunological and histological biomarkers haved. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to measure and do not constitute standard practice. Emer-
ging evidence indicates that peripheral blood cells reflect
the inflammatory status of patients, and they are predic-
tors of prognosis in cancer patients. The association
between pretreatment peripheral leukocytes (including
neutrophils, lymphocytes and platelets) and prognosis has
been observed in various cancers, including colon cancer,
melanoma and pancreatic carcinoma. In addition, systemic-
inflammation-based scores such as Glasgow prognostic
score (GPS), neutrophil lymphocyte ratio (NLR), and plate-
let lymphocyte ratio (PLR) have prognostic value in cancer
patients [5].
Regarding HCC, preoperative elevated NLR is associ-
ated with short disease-free survival (DFS) and overall
survival (OS) after hepatectomy or liver transplantation
[6,7]. Likewise, increased C-reactive protein or monocyte
count has been linked with poor prognosis [8,9]. Mono-
cytes play an important role in innate immunity and exhibit
prognostic value in cancers. High pretreatment monocyte
count is an independent factor of poor prognosis for pa-
tients with colorectal liver metastasis, cervical cancer, mel-
anoma, and HCC [9-12]. In fact, circulating monocytes
predict incident cancer and mortality even in healthy indi-
viduals [13].
The aim of the present study was to evaluate whether el-
evated preoperative peripheral monocyte count predicts
poor prognosis in HCC patients after hepatic resection, es-
pecially in hepatitis B virus (HBV)-associated HCC.Methods
Study population
We enrolled 351 patients with newly diagnosed HCC
treated with hepatectomy at The First Affiliated Hospital,
Sun Yat-Sen University, Guangdong, China between 2006
and 2009. All specimens were histologically proven to be
HCC after surgery. The routine workup was done within
7 days before surgery, which included a complete physical
examination, hematological and biochemistry profiles,
abdominal ultrasound and computed tomography (CT)
or magnetic resonance imaging (MRI), chest X-ray or
CT scan. Final diagnosis of HCC was made by patho-
logical examination of biopsy specimens. All patients
were >18 years of age, with complete clinical and labora-
tory data. No patients had any coexistent hematological
disorders or known active infection before treatment, en-
suring that the monocyte count was representative of the
normal baseline value. In addition, patients with mixed
HCC and cholangiocarcinoma and patients with no
follow-up data were excluded. Informed consent was ob-
tained, and procedures were carried out with prior ap-
proval of the Ethics Committee of the First Affiliated
Hospital of Sun Yat-sen University (Guangzhou, China).Treatment and follow-up
Hepatectomy was performed on all patients with intent
to cure, and tumor thrombectomy or combined dia-
phragmatic resection was carried out when necessary.
Surgical resection was defined as radical when there was
no evidence of distant metastases and tumor clearance
was both macroscopically and histologically complete.
Patients were regularly followed up at outpatient clinics
every 3 months for the first 2 years, every 6 months for
the next 3 years, and once annually thereafter. Patients
received a physical examination, liver ultrasound, chest
X-ray and AFP test at each follow-up. Abdominal CT scan
was performed every 6–12 months or when recurrence
was suspected. Recurrence was defined as emergence of
clinical, radiological, and/or pathological diagnosis (tissues
obtained by ultrasound-guided fine-needle aspiration) of
tumor. Once recurrence was confirmed, salvage treat-
ments including re-operation, percutaneous ablation
(ethanol injection, radiofrequency ablation, or microwave
ablation) or TACE were selected as needed.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 16.0 (SPSS, Chicago, IL, USA). Receiver
operating characteristic (ROC) curve analysis was per-
formed to select the most appropriate cut-off value of
monocyte count to stratify patients at a high risk of
tumor recurrence. At each value, sensitivity and specifi-
city were plotted, thus generating an ROC curve. The
score closest to the point with both maximum sensitivity
and specificity was selected as the cut-off value. The χ2
test was used to compare categorical variables. DFS and
OS were calculated from the date of surgery to the date of
recurrence, or HCC-associated death, respectively. Sur-
vival curves were plotted using the Kaplan–Meier method
and compared using the log-rank test. The Cox propor-
tional hazards model was used to determine independent
prognostic factors on the basis of variables selected on
univariate analysis. P < 0.05 was considered significant.
Results
Patient and tumor characteristics
There were 310 (88.3%) male and 41 (11.7%) female pa-
tients. The mean age of patients was 50.1 years (range:
21–79 years). Two hundred and fifty-six patients (72.9%)
developed recurrence while 222 (63.2%) died during
follow-up. Hepatitis B surface antigen (HBsAg) was posi-
tive in 302 patients (86.0%) and 269 (76.6%) patients had
underlying cirrhosis. Increased AFP (>200 ng/ml) was
found in 190 cases (54.1%) and 75 (21.4%) patients had ≥2
tumors in the liver. Mean tumor size (greatest dimension)
was 89.0 mm (range: 10–300 mm), with 281 (80.1%) pa-
tients having tumors >50 mm. With regard to tumor dif-
ferentiation according to Edmonson stage, there were 271
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Macroscopic vessel invasion into the portal vein, hepatic
vein or inferior vena cava was found in 90 patients
(25.6%). Details of features are shown in Table 1.
Relationship between clinicopathological features and
monocyte status
The median monocyte count was 600/mm3, which was
almost twice as high as the standard used by Sasaki et al.
[9]. To exclude empirical bias, we used ROC curve ana-
lysis to determine the optimal cut-off value for elevated
monocyte count. A cut-off value of 545/mm3 corre-
sponded to the maximum joint sensitivity and specificity
on the ROC plot (Figure 1). Clinicopathological features
of patients with different monocyte status are summarized
in Table 1. None of the commonly used clinicopathologi-
cal features (age, gender, Edmonson grade, HBsAg status,
surgical margin, capsulation, tumor number and cirrhosis)
were significantly different between the two groups. How-
ever, patients with elevated monocyte counts tended to








AFP (ng/ml) <200 161
≥200 190
Edmonson grading I-II 271
III-IV 80
Tumor size <5 cm 70
≥5 cm 281
Surgical margin <1 cm 122
≥1 cm 229






Tumor number Single 276
Multiple 75
Macrovascular invasion Absent 261
Present 90Risk factors for prognosis of HCC after hepatectomy
For all patients, the 1-, 3- and 5-year DFS was 44%, 30%
and 27%, respectively, and the 1-, 3- and 5-year OS was
70%, 43%, 36%, respectively. Univariate analysis (Table 2)
revealed that macrovascular infiltration, monocyte counts
≥545/mm3, surgical margin <1 cm, AFP ≥200 ng/ml,
tumor size ≥5 cm, non-capsulation (tumor had no capsu-
lation or ruptured during surgery), multiple tumors, and
macrovascular invasion were associated with significantly
poorer DFS. Similarly, monocyte counts ≥545/mm3, surgi-
cal margin <1 cm, tumor size ≥5 cm, non-capsulation, and
multiple tumors predicted poor OS.
On multivariate analysis, four parameters including
monocyte counts ≥545/mm3, tumor size ≥5 cm, non-
capsulation, and multiple tumors were independent
prognostic factors of poor DFS and OS.
DFS and OS according to monocyte status
The 1-, 3- and 5-year DFS rate was 58%, 41% and 35% for
patients with monocyte counts <545/mm3, and 36%, 23%
and 21% for patients with monocyte counts ≥545/mm3,s with different monocyte counts


























Figure 1 Receiver operating characteristic curve for
determination of the cut-off value for monocyte in patients
with hepatocellular carcinoma (HCC) after hepatic resection.
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year OS rate was 79%, 53% and 46% for patients with
monocyte counts <545/mm3, and 64%, 36%, 29% pa-
tients with monocyte counts ≥545/mm3. Both DFS and
OS of patients with monocyte counts <545/mm3 were
significantly better than for patients with monocyte
counts ≥545/mm3 (P < 0.001) (Figure 2).
Subgroup analysis according to the HBV infection and
cirrhosis status
To clarify the subgroups of patients negatively influ-
enced by preoperative peripheral blood monocyte
counts, we classified patients according to accompanying
liver disease (HBsAg positive, n = 302; HBsAg negative,
n = 49) and underlying cirrhosis (cirrhosis, n = 269; non-
cirrhosis, n = 82). DFS after hepatic resection of HBV-
infected patients was significantly better for those with a
peripheral blood monocyte count <545/mm3 (P < 0.001),
but DFS did not differ between patients without HBsAg
infection within groups (P = 0.607). In contrast to the re-
sults of Sasaki et al., we found that DFS was significantly
improved for the patients with a peripheral blood mono-
cyte count <545/mm3, whether or not cirrhosis was
present (P = 0.002 vs P = 0.018) (Figure 3).
Discussion
We demonstrated that elevated monocyte count inde-
pendently predicted worse survival in HCC patients
treated with hepatic resection, which concurs with a
previous study by Sasaki et al. [9]. In addition, tumor
size ≥5 cm, non-capsulation, and multiple tumors were
also independent prognostic factors of poor DFS and OS.
Numerous clinical and experimental studies have indi-
cated that inflammation is a critical component of tumorprogression. Inflammatory markers such as C-reactive
protein have been suggested as surrogate markers for
HCC [8]. Likewise, subsets of peripheral blood cells have
been found to be predictors of prognosis. Elevated NLR
was shown to be an indicator of poor outcome in pa-
tients undergoing hepatic resection for colorectal liver
metastasis and curative resection for HCC [14,15]. An
elevated neutrophil, monocyte or leukocyte count was
associated with poor survival in patients with metastatic
melanoma [12]. In addition, a higher pretreatment circu-
lating monocyte count was independently associated
with poor prognosis in patients with locally advanced cer-
vical squamous cell carcinoma and HCC [9,10]. However,
in all of these studies, the cut-off value for monocyte
count was based on a median value of circulating mono-
cyte count [10]. In the present study, the median mono-
cyte count was two times higher than that of Sasaki et al.
To exclude empirical bias, we used ROC curve to deter-
mine the optimal cut-off value to predict HCC recurrence
after hepatectomy.
Monocyte count can be easily measured by routine
preoperative blood workup and is a strong prognostic
factor for a number of malignancies, such as colorectal
cancer with liver metastasis and melanoma. With regard
to HCC, Sasaki et al. first reported that monocyte count
was a useful prognostic indicator in HCC patients [9].
In that study, a preoperative absolute peripheral blood
monocyte count >300/mm3 was shown to be an inde-
pendent prognostic indicator of tumor recurrence, es-
pecially in patients with HCC accompanying liver
cirrhosis [9]. In their series, serum hepatitis C antibody
was positive in 100 (65.4%) of the 153 tested patients
and HBV infection was positive in only 23.74% (47/198)
patients, which was different from our data (86%, 302/
351 patients). From subgroup analysis we found that el-
evated monocyte predicted early recurrence whether or
not cirrhosis was present, which was different from the
study of Sasaki et al. Patients in these two studies have a
different background of cirrhosis, which might account
for the difference. In addition, we found that elevated
monocyte count predicted poor prognosis in HBV-
positive HCC patients, but not in negative ones. This is
a novel finding.
The present study confirms that preoperative mono-
cyte count is an independent prognostic factor for HCC,
especially in patients with an HBV background. After
surgery, too many factors influence postoperative periph-
eral blood monocyte count, such as bleeding, shortage or
overuse of liquid replacement, and sepsis. Therefore, post-
operative peripheral blood inflammatory cells have not
been used often to predict prognosis as the preoperative
counterparts, although there are a few such reports
[16-18]. In fact, in the study of Lee et al., monocyte count
significantly increased after surgery, but the authors did
Table 2 Univariate and multivariate analysis of clinicopathological parameters influencing prognosis










Gender Male 0.25 0.064
Female
Age <50 years 0.079 0.078
≥50 years
HBs-Ag Negative 0.412 0.978
Positive
AFP (ng/ml) <200 0.021 0.209
≥200
Edmonson grading I-II 0.277 0.788
III-IV
Tumor size <5 cm < 0.001 < 0.001 1.991 (1.383-2.867) 0.001 < 0.001 1.919 (1.291-2.582)
≥5 cm
Surgical margin <1 cm 0.001 0.002
≥1 cm
Liver cirrhosis Absent 0.505 0.91
Present
Monocyte count (/mm3) <545 < 0.001 0.01 1.393 (1.083-1.793) < 0.001 0.002 1.578 (1.187-2.097)
≥545
PVTT Absent 0.545 0.911
Present
Capsulation Capsulated < 0.001 < 0.001 1.597 (1.231-2.071) 0.002 < 0.001 1.793 (1.371-2.345)
Non-caspulated
Tumor number Single < 0.001 0.005 1.513 (1.134-2.019) < 0.001 < 0.001 1.771 (1.312-2.392)
Multiple
Macrovascular invasion Absent 0.012 0.086
Present
CI, confidence interval; HR, hazard ratio.
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survival [18]. We think it might be unsuitable to use post-
operative monocyte count to predict prognosis for too
many confounding factors.
The exact pathophysiology for the association between
high monocyte counts and poor prognosis is not well
understood. There are several possible explanations.
First, it has been hypothesized that activation of the in-
nate immune system through mobilization of monocytes
to tissue macrophages develops an inflammatory state
associated with increased risk of cancer and mortality
[19-21]. Tumor-associated macrophages (TAMs), which
arise from blood monocytes, appear to play a crucial role
in the tumor microenvironment and can educate and
control invading leukocytes to promote angiogenesis,
viability, motility and invasion [19-21]. Monocytes are
actively attracted to the tumor site and differentiate into
TAMs as a result of the production of cytokines andchemokines by tumor cells, such as monocyte chemo-
attractant protein-1 [or chemokine CC ligand (CCL2)],
RANTES (or CCL5) and vascular endothelial growth
factor. TAMs are not only capable of killing tumor cells
and releasing angiostatic compounds, but can exert
pro-tumor effects through the secretion of immunosup-
pressive cytokines and angiogenic factors. Unfortu-
nately, the pro-tumor effects of TAMs often outweigh
the tumor-inhibiting effects during tumor development.
The number of TAMs has been shown to correlate with
poor prognosis [19-22]. Second, elevated CD14+CD16+
monocytes (a minor blood monocyte subpopulation) cor-
relate with TAM infiltration. These monocytes express
higher levels of adhesion molecules and scavenger recep-
tors, which enable them to adhere to endothelial cells, and
they also express high levels of growth-factor- and
angiogenic-factor-related genes. All these characteristics in-
dicate that CD14+CD16+ monocytes have protumorigenic
Figure 2 Disease-free survival and overall survival of 351 HCC patients after hepatectomy with different monocyte. The patients were
divided into monocyte ≥ 545/mm3 and monocyte < 545/mm3 group by the optimal cut-off value of monocyte. (A) Disease-free survival of
patients with monocyte ≥ 545/mm3 was shorter than those with monocyte < 545/mm3 (P < 0.001, log-rank). (B) Overall survival of patients
with monocyte ≥ 545/mm3 was also shorter than those with monocyte < 545/mm3 (P < 0.001, log-rank).
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sion and poor patient outcome [23]. Third, a fraction of
monocytes/macrophages in peritumoral stroma expresses
surface programmed death ligand (PD-L)1 molecules in tu-
mors from patients with HCC. The PD-L1+ monocytes ef-
fectively suppress tumor-specific T cell immunity and
contribute to the growth of human tumors in vivo, which
can be reversed by blocking PD-L1 on these monocytes.
Moreover, PD-L1 expression on tumor-infiltrating mono-
cytes is increased with disease progression, and the inten-
sity of the protein is associated with high mortality and
reduced survival in HCC patients. Thus, expression of PD-
L1 on activated monocytes/macrophages may represent a
novel mechanism that links the proinflammatory response
to immune tolerance in the tumor milieu [24]. In short,
monocytes might contribute to the compromised antitu-
mor microenvironment, thus promoting tumor progress.
HCC shows low responsiveness to standard chemo-
therapeutic agents or radiotherapy, like other tumors (such
as osteosarcoma, lung cancer, and breast cancer). There-
fore, a high preoperative monocyte count does not necessi-
tate neoadjuvant therapy [25-27]. Instead, postoperative
adjuvant therapy might be considered. Nevertheless, for
HCC patients after curative resection, there is no consensus
on the use of adjuvant therapy outside of clinical trials [3].
However, studies have shown that HCC patients with a
high risk of recurrence are likely to benefit from postopera-
tive adjuvant treatment such as chemotherapy, TACE,
or antiviral therapy [28,29]. A study from Xia et al. [30]
showed that adjuvant therapy with capecitabine postponed
recurrence of HCC after curative resection. In addition, an
adjuvant intraportal venous chemotherapy regimen ofcisplatin, interferon-α, doxorubicin, and 5-fluorouracil
(PIAF) for HCC patients with portal vein tumor thrombus
(PVTT) following hepatectomy, plus portal thrombectomy,
significantly delayed recurrence and prolonged survival
[31]. Risk of HCC recurrence after potentially curative re-
section was higher in the setting of high viral replication
and ongoing inflammatory activity in the liver. In a meta-
analysis, antiviral therapy with interferon was found to im-
prove 1-, 2- and 3-year recurrence-free survival by 7.8%,
35.4% and 14.0%, respectively (all P < 0.01) [32]. Likewise,
oral antiviral drugs (including lamivudine, adefovir and
entecavir) showed potential beneficial effects after cura-
tive treatment of HBV-related HCC in terms of tumor
recurrence, liver-related mortality, and OS [33,34]. Al-
though it remains unclear whether TACE actually de-
creases the risk of tumor recurrence, it has been
reported that postoperative TACE prevents early recur-
rence, while antiviral therapy prevents late recurrence of
HCC. Combination of antiviral therapy and TACE is sug-
gested for prevention in HCC patients at high risk of re-
currence [28,29,35]. Multicenter studies evaluating the
effects of adjuvant kinase inhibitor treatments with sorafe-
nib after curative resection or tumor ablation are currently
underway (STORM study from Bayer) [4]. Until the re-
sults of these studies are available, the role of adjuvant or
neoadjuvant treatments with kinase inhibitors in the pre-
vention of tumor recurrence in the setting of potentially
curative treatments for HCC remains unknown.
There were two limitations to our study. First, we were
not able to split our data set into a training data set and a
test data set for statistical validation because of the small
number of patients, which we hope to validate in future
Figure 3 Subgroup analysis of disease-free survival of 351 HCC patients after hepatectomy with different monocyte based on HBV or
cirrhosis status. (A) monocyte count could not separate patients with different DFS rates in patients with HBV negative group (P = 0.858).
(B) By contrast, monocyte count predicted different DFS rates in patients with HBV positive group (P < 0.001). (C) In addition, DFS was
significantly better for the patients with a peripheral blood monocyte count < 545/mm3 than those with monocyte ≥ 545/mm3 in non-cirrhosis
group (P = 0.018). (D) DFS was also significantly better for the patients with a peripheral blood monocyte count < 545/mm3 than those with
monocyte ≥ 545/mm3 in cirrhosis group (P = 0.002).
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that elevated monocyte count predicted early recurrence,
and that these patients might benefit from postoperative
adjuvant therapy, we were not able to test this hypothesis,
which we hope to prove in future clinical trials.Conclusions
Our results show that the absolute number of peripheral
blood monocytes may be related to tumor progression
and is an independent risk factor for recurrence of HCC
after hepatic resection, especially for patients with
HBV infection. Future clinical trials to test the efficacy
of postoperative adjuvant treatment in HCC patients
with an elevated preoperative monocyte count might
be considered.Abbreviations
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GPS: Glasgow prognostic score; HBV: Hepatitis B virus; HCC: Hepatocellular
carcinoma; MRI: Magnetic resonance imaging; NLR: Neutrophil lymphocyte
ratio; OS: Overall survival; PIAF: Cisplatin, interferon-α, doxorubicin, and
5-fluorouracil; PLR: Platelet lymphocyte ratio; PVTT: Portal vein tumor
thrombus; ROC: Receiver operating characteristic; TACE: Transcatheter
arterial chemoembolization; TAM: Tumor-associated macrophage.
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